Evidence map›Paper›PMID 29764222›Full record

SynthesisCurrent medical research and opinion2018

Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.

Rohini Sharma, Lars Wilkinson, Hrvoje Vrazic, Evan Popoff, Sandra Lopes, Steve Kanters, Eric Druyts

2 registry-linked trialsOpen access · greenAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Current medical research and opinion, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01930188. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01930188 phase3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)

Ran2013Enrolled1,231Registered outcomes6Posted comparisons2ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsPlacebo, semaglutide, Sitagliptin
PMID 29862621PMID 30615985PMID 28385659PMID 29748996PMID 30865526PMID 29766634PMID 30938762PMID 29907893other papers from this trial
Open the trial in the graph
NCT02648204 phase3completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Ran2016Enrolled1,201Registered outcomes28Posted comparisons6ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsDulaglutide, semaglutide
PMID 30615985PMID 29246950PMID 30362224PMID 30865526PMID 29397376PMID 31168765PMID 29557057PMID 30927241other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019 · on this map
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Rohini Sharmaa Precision Xtract , Vancouver , BC , Canada.
Lars Wilkinsonb Novo Nordisk A/S , Søborg , Denmark.
Hrvoje Vrazicb Novo Nordisk A/S , Søborg , Denmark.
Evan Popoffa Precision Xtract , Vancouver , BC , Canada.
Sandra Lopesb Novo Nordisk A/S , Søborg , Denmark.
Steve Kantersa Precision Xtract , Vancouver , BC , Canada.
Eric Druytsc Precision Xtract , Boston , MA , USA.
Novo Nordisk (Denmark) · DKPrecision Nanosystems (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTreatment intensification with additional anti-diabetic agents is recommended in type 2 diabetes (T2D) for patients inadequately controlled on metformin monotherapy. The present network meta-analysis (NMA) evaluated comparative efficacy and safety of once-weekly semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) in T2D patients inadequately controlled with metformin.

methodsRandomized controlled trials with ≥20 weeks duration were searched in EMBASE, MEDLINE, and CENTRAL. Primary efficacy outcomes were: change from baseline in HbA

resultsEight trials were found eligible for this NMA. Statistically significant reductions in HbA1c were observed with both 1.0 mg and 0.5 mg doses of once-weekly semaglutide when compared to SGLT-2is. The mean differences in change from baseline in HbA

conclusionOnce-weekly semaglutide treatment is significantly better compared to SGLT-2is in achieving adequate glycemic control in T2D patients inadequately controlled with metformin monotherapy.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHumansHypoglycemic AgentsMetforminSemaglutideSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeGlucagon-Like PeptidesHypoglycemic AgentsMetforminSemaglutideSodium-Glucose Transporter 2 InhibitorsGLP-1glucagon-like peptide-1 analogOnce-weekly semaglutideSGLT-2 inhibitorsSUSTAIN 2SUSTAIN 7type 2 diabetes

Identifiers

PMID29764222
OpenAlexW2804862484

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.